Big pharma has spent a lot of money founding or funding small firms recently. This is partly a strategic choice on the part of management - some have a surfeit 11 May 2018
A newcomer on the biologics scene expressing a vision to become a global player is nothing new, but it is a bold ambition when coming from CinnaGen, an Iranian 30 April 2018
Since the inception of the biopharmaceutical age in the 1980s, the share of the market held by large molecules has risen steadily to about a fifth, and growth i 23 April 2018
It was no fluke when Celltrion Healthcare became the first drug developer to win approval for a biosimilar monoclonal antibody (mAb) from the European Medicines 13 April 2018
If it were ever doubted that cannabis-based therapies would one day occupy space in certain specialists’ armamentaria, that time has now certainly passed. 11 April 2018
For many patients.brands like Nurofen (ibuprofen) and Claritin (loratadine) are household names.They retain a prominent place on supermarket shelves and sell ex 5 April 2018
Cardiovascular (CV) disease is the world’s biggest killer that will demand a specific and concerted effort if drugmakers are to tackle it, but one company is di 19 March 2018
The Pharma Letter discovers that Takeda’s vision in neuroscience is reminiscent of its approach in producing global vaccines, another massive healthcare challen 14 March 2018
For years, pharmaceutical companies have struggled to develop new treatments for the second most common type of leukemia diagnosed in adults and children, acute 1 March 2018
With 2017 sales growth at 21.5% and shares in the company up 96% since the beginning of last year, everything is going right for Ipsen at the moment. 21 February 2018
Sometimes a device or diagnostic comes along that even the most drug-centric of pharma companies cannot afford to ignore, but when this innovation threatens to 16 February 2018
The Pharma Letter speaks to Sjaak Vink, the chief executive of the SocialMedwork, a bold and ambitious start-up that wants to stop borders being a barrier for p 26 January 2018
With sales of 97 billion yen ($970 million) for the first half of 2017, a rise of nearly 50% on the previous year, the gastroenterology product Entyvio (vedoliz 11 January 2018
This year marks the 350th anniversary of German science and technology group Merck KGaA, a milestone that will remind the industry and wider world that it is th 10 January 2018
In today’s world, cheap insults from people in high places – whether justified and evidence-backed or not – can do harm to the reputation and market value of ph 15 December 2017
There are a few striking similarities between the world’s biggest biotech firm focused on rare diseases, and an emerging clinical stage pharma company that was 5 December 2017
Mads Krogsgaard Thomsen, Novo Nordisk employee for over a quarter of a century, says he has been through all the miserable failures as well as the successes of 28 November 2017
The convergence of two trends makes Chris Claxton, the vice president of investor relations at UK-based Horizon Discovery, believe that his company is in the ri 20 November 2017
Boosted by his firm’s positive Phase III presentation at last week’s ATTR meeting, Alnylam Pharmaceuticals’ chief medical officer Akshay Vaishnaw won’t commit t 10 November 2017
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.